Current research indicates that DPP-4 inhibitors can help with hyperlipidemia, hypertension, calcified aortic valve disease, and coronary atherosclerosis; however, their potential benefit for HF is still up for debate. This evidence concerns the gene DPP4 and coronary atherosclerosis.